Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
UBE2C
REST API REST API
Homo sapiens
UBE2C is differentially expressed in 314 experiments: 119 organism parts: bone marrow, thymus, ... (117 more);, 220 disease states: normal, colon carcinoma, ... (218 more);, 111 cell types 347 cell lines 34 compound treatments and 71 other conditions.
Synonyms UBCH10
Orthologs Ube2c (Rattus norvegicus)   UBE2C_BOVIN (Bos taurus)   Ube2c (Mus musculus)   UBC11 (Saccharomyces cerevisiae)   F6PKV2_CIOIN (Ciona intestinalis)   UBE2U (Danio rerio)   vih (Drosophila melanogaster)   ube2c (Xenopus laevis)   UBE2C (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, ligase activity, anaphase-promoting complex, cell division, protein binding, acid-amino acid ligase activity, protein ubiquitination, mitotic cell cycle, positive regulation of exit from mitosis, spindle organization, anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process, cyclin catabolic process, ATP binding, cell cycle, exit from mitosis, mitosis, ubiquitin-protein ligase activity, nucleotide binding, nucleoplasm, cell cycle checkpoint, mitotic cell cycle spindle assembly checkpoint, ubiquitin-dependent protein catabolic process, protein K11-linked ubiquitination, negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle, protein K48-linked ubiquitination, activation of anaphase-promoting complex activity, free ubiquitin chain polymerization, positive regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle, phosphatidylinositol-mediated signaling, regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
InterPro Term UBQ-conjugat_E2
UniProt Accession Q5TZN3, O00762, A6NP33, E1P5N7
Search EB-eye ENSG00000175063
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (43 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-24147, E-GEOD-5258, E-MTAB-37
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
BT20
2
E-MTAB-37, E-MTAB-62
K562
1
2
E-MTAB-37, E-GEOD-24147, E-GEOD-96
RPMI 8226
1
E-MEXP-921
LNCaP
1
E-GEOD-14990
341 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-500, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (51 experiments)

Factor Value U/D Experiments
CD8+ T cell
1
3
E-AFMX-5, E-MTAB-25, E-GEOD-19069, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
1
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD4+ T cell
2
3
E-AFMX-5, E-GEOD-16190, E-MTAB-24, E-MTAB-25, E-TABM-145 ... (5 experiments)
unstimulated polymorphonuclear leukocyte
1
E-GEOD-935
105 more value(s).


Disease state

studied in E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (71 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-GEOD-2514, E-MTAB-37, E-MTAB-62, E-MEXP-231
cervical carcinoma
3
E-MTAB-62, E-GEOD-5823, E-MEXP-1331
glioblastoma
1
3
E-GEOD-4290, E-GEOD-6014, E-MEXP-567, E-GEOD-4412
colon carcinoma
1
3
E-MTAB-62, E-GEOD-3726, E-MTAB-57, E-MTAB-37
breast carcinoma
2
E-GEOD-7307, E-GEOD-5823
malignant melanoma
2
E-GEOD-3189, E-MTAB-62
214 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (22 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
control
1
2
E-GEOD-3284, E-GEOD-995, E-GEOD-4006
TNF
1
E-GEOD-15205
oligomycin
1
E-MEXP-2285
unknown
1
E-GEOD-7307
17beta-estradiol
4
1
E-GEOD-4006
28 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-2191, E-GEOD-4619, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, E-GEOD-3140, ... (6 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-17476, E-MEXP-421, E-GEOD-22593, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-12773, E-GEOD-20504, ... (12 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-2748

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-9723, E-MEXP-561

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321, E-GEOD-762

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-2487, ... (6 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-4883, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-15799, ... (6 experiments)

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-3494, E-TABM-43, E-GEOD-1561, ... (8 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.339 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM